Skip to content

Application of Rebazolam benzenesulfonic acid for injection in hysteroscopy

Application of Rebazolam benzenesulfonic acid for injection in hysteroscopy

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040348
Enrollment
Unknown
Registered
2020-11-28
Start date
2020-12-15
Completion date
Unknown
Last updated
2021-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sedation

Interventions

1:Sufentanil + Remazolam
2:Sufentanil + propofol
3:Sufentanil + Remazolam

Sponsors

Shiyan People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. The signing of the informed consent; 2. ASA class for I or II; 3. BMI18 ~ 28 kg/m2; 4. aged 18 to 65 years old; 5. received hysteroscopy diagnosis and treatment.

Exclusion criteria

Exclusion criteria: (1) Unaccompanied or guardian, unable to communicate with people with abnormal hearing and vision; (2) Patients with obvious respiratory and circulatory dysfunction, abnormal blood routine and blood biochemical indicators before operation; (3) persons suffering from severe neuropsychiatric diseases; (4) Take benzodiazepines or opioids every day for 1 month or for nearly 3 months intermittently; (5) Allergic or contraindicated to benzodiazepines, opioids, propofol, flumazine, naloxone and other drugs and their components; (6) judged: patients with difficult airway management improved markov score level III and above.

Design outcomes

Primary

MeasureTime frame
haemodynamics;Ramsay scores;VAS score;improved OAA/S score;Times of drug addition;

Countries

China

Contacts

Public ContactXiao Yun
xiaoyun5598@163.com+86 15907287568

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026